Figure 6.

Adoptive Transfer of p53 scTCR-Modified Human T Cells Eradicates Established Tumors in a Xenograft Model of Osteosarcoma

NSG mice were injected (s.c.) with Saos2/143 tumor cells and infused (i.v.) with mock or scTCR-modified human bulk T cells as described in the Materials and Methods. All mice received IL-2 injection (i.p.) at days 7 and 14 after tumor challenge. (A) Growth and size of tumors after adoptive transfer of mock (left panel, n = 6 mice) or TCR-specific (right panel, n = 8) T cells. Representative data from three independent experiments are shown. (B) Representative flow plots show the frequency of spleen-infiltrating TCR-specific T cells as percent of TCRVβ3⁺ T cells (CD8⁺, left panel; CD4⁺, right panel) at day 178 after adoptive T cell transfer. (C) Cytolytic activity of ex-vivo antigen-specific memory T cells (described in B) in response to T2 cells pulsed with 10 μM p53_264–272 or irrelevant HIV_476–484 peptide and Saos2/143 tumor cell line at the indicated CD8⁺Vβ3⁺-to-target ratio.